Teva Pharmaceutical Industries Ltd. (TEVA)
42.57
-1.93
(-4.34%)
USD |
NYSE |
Nov 16, 16:00
42.31
-0.26
(-0.61%)
Pre-Market: 06:32
Teva Pharmaceutical Industries Enterprise Value : 62.58B for Nov. 16, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 16, 2026 | 62.58B |
| November 13, 2026 | 64.84B |
| November 12, 2026 | 63.84B |
| November 11, 2026 | 63.37B |
| November 10, 2026 | 62.38B |
| November 09, 2026 | 63.05B |
| November 06, 2026 | 62.63B |
| November 05, 2026 | 61.66B |
| November 04, 2026 | 61.74B |
| November 03, 2026 | 61.81B |
| November 02, 2026 | 60.40B |
| October 30, 2026 | 62.02B |
| October 29, 2026 | 61.30B |
| October 28, 2026 | 59.55B |
| October 27, 2026 | 60.04B |
| October 26, 2026 | 59.53B |
| October 23, 2026 | 58.90B |
| October 22, 2026 | 59.83B |
| October 21, 2026 | 60.31B |
| October 20, 2026 | 60.58B |
| October 19, 2026 | 61.11B |
| October 16, 2026 | 61.33B |
| October 15, 2026 | 60.88B |
| October 14, 2026 | 60.42B |
| October 13, 2026 | 61.04B |
| Date | Value |
|---|---|
| October 12, 2026 | 60.95B |
| October 09, 2026 | 60.87B |
| October 08, 2026 | 58.71B |
| October 07, 2026 | 58.63B |
| October 06, 2026 | 58.57B |
| October 05, 2026 | 59.19B |
| October 02, 2026 | 59.04B |
| October 01, 2026 | 58.78B |
| September 30, 2026 | 59.12B |
| September 29, 2026 | 59.60B |
| September 28, 2026 | 58.52B |
| September 25, 2026 | 58.88B |
| September 24, 2026 | 60.08B |
| September 23, 2026 | 58.67B |
| September 22, 2026 | 59.26B |
| September 21, 2026 | 59.89B |
| September 18, 2026 | 58.63B |
| September 17, 2026 | 58.88B |
| September 16, 2026 | 58.11B |
| September 15, 2026 | 58.95B |
| September 14, 2026 | 58.33B |
| September 11, 2026 | 56.33B |
| September 10, 2026 | 55.57B |
| September 09, 2026 | 56.15B |
| September 08, 2026 | 56.05B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Merck & Co., Inc. | 400.43B |
| Bristol Myers Squibb Co. | 160.86B |
| Eli Lilly & Co. | 1.392T |
| Pfizer Inc. | 213.20B |
| Sanofi | 126.72B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 232.07M |
| Revenue (Quarterly) | 4.335B |
| Total Expenses (Quarterly) | 4.104B |
| EPS Diluted (Quarterly) | 0.1953 |
| Gross Profit Margin (Quarterly) | 55.27% |
| Profit Margin (Quarterly) | 5.35% |
| Earnings Yield | 0.98% |
| Operating Earnings Yield | 6.62% |
| Normalized Earnings Yield | 3.695 |